2022 SODIUM-HF TRIAL Reduction of dietary sodium to less than 100 mmol in heart failure International, open-label, randomised, controlled trial Objective: To evaluate if a low-sodium diet (<1500 mg daily) compared to usual care in ambulatory patients with heart failure would prevent adverse cardiovascular events 806 806 er en meget Inclusion criteria: Age 18 years with chronic heart failure regardless of LVEF; New York Heart Association (NYHA] functional class 2-3 and receiving optimally tolerated guideline-directed medical treatment mere end Patients VS Low sodium diet (n=397) Usual care (n=409) PRIMARY OUTCOME Cardiovascular-related hospitalization, cardiovascular-related emergency department visit or all-cause death % HR 0.89; 95% CI 0.63–1.26; P=0.53 SECONDARY OUTCOMES All-cause mortality at 12 months % HR 1.38; 95% CI 0.73-2.60; P=0.32 Cardiovascular-related hospitalization HR 0.82; 95% CI 0.54–1.24; P=0.36 Cardiovascular-related emergency department visits HR 1.21; 95% CI 0.60-2.41; P=0.32 Conclusion: In ambulatory patients with heart failure, a dietary intervention to reduce sodium intake did not reduce clinical events; however, there was a small improvement in quality of life and NYHA functional class JA Ezekowitz et al. Lancet 2022 April 9, 399 (10333): 1391-1400